Please login to the form below

Not currently logged in
Email:
Password:

Novartis' Ilaris launched in UK

Novartis has announced that its CAPS treatment, Ilaris (canakinumab), has been launched in the UK

Novartis has announced that its treatment for cryopyrin-associated periodic syndrome (CAPS) in adults and children over four years old, Ilaris (canakinumab), has been launched in the UK.

The UK launch was preceded by an accelerated EU decision on Ilaris (canakinumab) and approvals in the US and Switzerland, where the therapy was granted priority review in October 2009 in view of the significant unmet medical need. 

Ilaris (canakinumab) is a fully human monoclonal antibody given by injection under the skin once every two months. It is the only therapy approved in the EU for young CAPS patients and for patients with neonatal-onset multi-system inflammatory disease (NOMID) –  the most debilitating form of CAPS. 

Dr Helen Lachmann of the UK National Amyloidosis Centre at the Royal Free and University College Medical School, London said: "By effectively switching off disease activity, canakinumab has the potential to transform CAPS patients' lives by offering long-term control of this rare disease."

"In the pivotal CAPS study, the majority of patients saw an improvement in symptoms within 24 hours of receiving a single dose of canakinumab. After two weeks the disease was barely detectable in the blood and the remission of symptoms was sustained for six months," she continued. 

It is believed CAPS occurs in around 2,500 people in the EU. However, the rarity of the disease means that many of these patients may be undiagnosed. CAPS includes three auto-inflammatory disorders of increasing severity: familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID). Canakinumab is the only treatment available in the UK to treat all three disorders.

7th January 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics